In vivo acquisition of extended-spectrum beta-lactamase inSalmonella enteritidis during antimicrobial therapy

Barguellil, Farouk; Burucoa, Christophe; Amor, A.; Fauchère, Jean-Louis; Fendri, C.

doi:10.1007/bf01690879

Cited by 16 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few authors detected them in various serotypes of S. enterica (8,18,22,23), and all reported the presence of SHV-2. Several different TEM ESBLs have been found in this genus (4,5,36,49,57). In this paper, two isolates carrying SHV-2a of S. enterica serotype wien, originally from Libyan patients, are reported.…”

Section: Discussionmentioning

confidence: 96%

Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12

Nüesch‐Inderbinen

Kayser

Hächler

1997

Antimicrob Agents Chemother

144

View full text Add to dashboard Cite

Sixty isolates of Enterobacteriaceae resistant to beta-lactam antibiotics were collected over a period of 2 years in Switzerland and screened by hybridization for the carriage of SHV genes. Thirty-four positive strains were found, and their SHV genes were amplified and sequenced. SHV extended-spectrum beta-lactamases (ESBLs) were found: 13 strains contained SHV-2a, 12 harbored SHV-2, and SHV-5 was found twice. Four strains were shown to contain SHV-1. In addition, we report two new SHV variants, termed SHV-11 (non-ESBL) and SHV-12 (ESBL). In spite of the carriage of SHV ESBLs, many strains showed only low resistance to one or more third-generation cephalosporins. In addition, 26 did not transfer the blaSHV gene in mating experiments.

show abstract

Section: Discussionmentioning

confidence: 96%

Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12

Nüesch‐Inderbinen

Kayser

Hächler

1997

Antimicrob Agents Chemother

144

View full text Add to dashboard Cite

show abstract

“…However, it has been reported that 36.1% of Klebsiella pneumoniae isolates collected in a single South African hospital in 1998 and 1999 were ESBL producers (33). ESBLs have also been documented in Israel, Saudi Arabia, and a variety of North African countries (3,25,35,36,47,122,247,272). Outbreaks of Klebsiella infections with strains resistant to third-generation cephalosporins have been reported in Nigeria and Kenya without documentation of ESBL production (5,264).…”

Section: Global Epidemiologymentioning

confidence: 99%

Extended-Spectrum β-Lactamases: a Clinical Update

2005

View full text Add to dashboard Cite

SUMMARY Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by clavulanic acid. Typically, they derive from genes for TEM-1, TEM-2, or SHV-1 by mutations that alter the amino acid configuration around the active site of these β-lactamases. This extends the spectrum of β-lactam antibiotics susceptible to hydrolysis by these enzymes. An increasing number of ESBLs not of TEM or SHV lineage have recently been described. The presence of ESBLs carries tremendous clinical significance. The ESBLs are frequently plasmid encoded. Plasmids responsible for ESBL production frequently carry genes encoding resistance to other drug classes (for example, aminoglycosides). Therefore, antibiotic options in the treatment of ESBL-producing organisms are extremely limited. Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported. ESBL-producing organisms may appear susceptible to some extended-spectrum cephalosporins. However, treatment with such antibiotics has been associated with high failure rates. There is substantial debate as to the optimal method to prevent this occurrence. It has been proposed that cephalosporin breakpoints for the Enterobacteriaceae should be altered so that the need for ESBL detection would be obviated. At present, however, organizations such as the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) provide guidelines for the detection of ESBLs in klebsiellae and Escherichia coli. In common to all ESBL detection methods is the general principle that the activity of extended-spectrum cephalosporins against ESBL-producing organisms will be enhanced by the presence of clavulanic acid. ESBLs represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents.

show abstract

“…The sequential in vivo acquisition of ESBLs by S. enteritidis was first reported by Barguellil in Tunisia. The genes conferring resistance to β‐lactams, aminoglycosides and chloramphenicol were transferred together by conjugation [43].…”

Section: Discussionmentioning

confidence: 99%

Phage types, antibiotic susceptibilities and plasmid profiles of Salmonella typhimurium and Salmonella enteritidis strains isolated in Istanbul, Turkey

Anğ-Küçüker

Tolün

Helmuth

et al. 2000

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

In vivo acquisition of extended-spectrum beta-lactamase inSalmonella enteritidis during antimicrobial therapy

Cited by 16 publications

References 15 publications

Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12

Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12

Extended-Spectrum β-Lactamases: a Clinical Update

Phage types, antibiotic susceptibilities and plasmid profiles of Salmonella typhimurium and Salmonella enteritidis strains isolated in Istanbul, Turkey

Contact Info

Product

Resources

About